02007nas a2200313   4500000000100000008004100001260004100042653001400083653001500097653001100112653001000123100001200133700001400145700001500159700001400174700001500188700001300203700001500216700001300231700001600244700001400260700001300274245008200287856006600369300001100435490000700446520121500453022002501668       2025                            d  bScientific Research Publishing, Inc.10aAntivenom10aEnvenoming10aSnakes10aGabon1 aOndo RO1 aNkilly GE1 aOliveira S1 aObiang PN1 aGuissou FR1 aOrema SD1 aBivigou WM1 aAnani UM1 aHevezogo JO1 aLawson JM1 aTchoua R00aEpidemiological Aspects and Management of Ophidien Envenimation in Libreville  uhttps://www.scirp.org/journal/paperinformation?paperid=143131  a99-1070 v133 a<p><strong>Introduction</strong>: In 2017, WHO reintegrated snake bites into neglected tropical diseases. Our objective was to describe the epidemiological characteristics of ophidian envenomations treated in Libreville from 01/01/2012 to 03/31/2019.&nbsp;</p>

<p><strong>Methodology</strong>: This was a retrospective descriptive multicenter study over 7 years (2012-2018) and prospective (1st quarter 2019) about 23 cases. All patients received for ophidian envenomation with key information for our study were included. Ethical considerations were respected.&nbsp;</p>

<p><strong>Results</strong>: We conducted our study on 23 cases of ophidian envenomation. The median age was 26 years. There was a slight male predominance with a sex ratio of 1.09. Bites were mainly nocturnal 34.78% of cases. The lower limb was most affected 73.91% of cases. Local syndrome was the most common clinical sign. Viperine syndrome accounted for 95.65% of cases. Biological tests were not often requested. Those who had c</p>

<p><strong>Conclusion</strong>: The establishment of therapeutic protocols and the accessibility to antivenom will contribute to improving the hospital management of these pathologies.</p>
  a2332-1806, 2332-1814